Monocentric analysis shows improved non-relapse mortality in patients with HCT-CI >3, indicating RIC and PTCy may enhance outcomes in this group.
Key Points
At 24 months, overall survival was 58% and progression-free survival was 55% among patients with HCT-CI >3.
Patients with acute myeloid leukemia represented 48% of the study cohort, highlighting disease prevalence.
Observational analysis revealed a significant association between a higher HCT-CI and reduced survival outcomes, underscoring the need for comprehensive assessments.
Graft-versus-host-disease occurred in 48% of cases, indicating potential complications that require management.